USPTO serial 79186567
LIPID INCODE
Reviewed by CopyMark Law Group
Reg. 5248111Status 709
- Filing date
- Status date
- Registration date
- Jul 25, 2017
- Examiner
- O'BRIEN, JENNIFER LYNN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with LIPID INCODE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Diagnostic preparations for medical or veterinary purposes; products, reagents and indicators for medical diagnostics, namely, preparations, reagents and biological indicators for monitoring the diagnosis of Familiar Hypercholesterolemia as well as DLAL (Deficiency in Lysosomal Acid Lipase) for medical or veterinary purposes; Diagnostic agents for medical purposes, namely, diagnostic agents for pharmaceutical use; testing materials for medical use, namely, medical diagnostic reagents and assays for testing of body fluids; pharmaceutical and veterinary products, namely, pharmaceutical products for the treatment of Hypercholesterolemia; food supplements for humans or animals; nutraceutical products for therapeutic use and as a dietary supplement, namely, nutraceuticals for the treatment of Hypercholesterolemia and nutraceuticals for use as a dietary supplement; Plasters for medical purposes, namely, material for dressings; disinfectants | SECTION 71 - CANCELLED | — |
| 010 | Surgical, medical, dental and veterinary instruments and apparatus, namely, medical instruments and apparatus for use in a genetic diagnostic kit in the diagnosis of Familiar Hypercholesterolemia as well as DLAL (Deficiency in Lysosomal Acid Lipase) procedures; suture materials; instruments and apparatus for medical diagnostics, namely, apparatus for medical diagnostic testing in the fields of Familiar Hypercholesterolemia as well as DLAL (Deficiency in Lysosomal Acid Lipase); automatic analyzers for medical diagnostics, namely, medical diagnostic instruments for the analysis of body fluids; apparatus for diagnostic testing for medical purposes, namely, medical diagnostic apparatus for testing DNA; diagnostic test kits for detecting diseases, namely, diagnostic kits consisting primarily of probes, buffers and reagents for use in genetic body fluids testing; apparatus for analyzing DNA in biological samples for medical use; apparatus for collecting samples of body fluids, namely, medical specimen collection devices in the nature of glass slides, cups or bags for the collection of blood or saliva samples; Medical specimen bags for testing purposes, namely, bags for medical use in storing blood or saliva samples; Medical specimen bags for testing purposes, namely, bags for medical use in collecting blood or saliva samples; Sample preparation device for medical diagnostic uses, namely, sample preparation columns for medical use; containers for medical samples, namely, blood and saliva containers for medical purposes; devices for taking samples for medical use, namely, medical devices for obtaining body fluid samples; urine sample testing instruments for medical diagnostics in the nature of medical diagnostic apparatus for testing DNA; containers specially designed for transporting samples containing living human cells; holders for sample containers, namely, specimen cup holders; capillary tubes for samples | SECTION 71 - CANCELLED | — |
| 042 | Medical and pharmaceutical research services; research and development services in the field of bacteriology; scientific research services for medical purposes in the field of Familiar Hypercholesterolemia, DLAL (Deficiency in Lysosomal Acid Lipase) and Cardiovascular Risks; chemical research and analysis; advisory services relating to pharmaceutical research; technical project study, namely, scientific study and research in the field of the prevention, treatment and management of Familiar Hypercholesterolemia, DLAL (Deficiency in Lysosomal Acid Lipase) and Cardiovascular Risks; medical research laboratory services; design and development of apparatus for medical diagnostics; computer-assisted diagnostic testing services, namely, diagnostic services in the field of Familiar Hypercholesterolemia, DLAL (Deficiency in Lysosomal Acid Lipase) and Cardiovascular Risks; Scientific laboratory services, namely, preparation of biological samples for research purposes; Scientific laboratory services, namely, preparation of biological samples for use in testing and analysis in research laboratories | SECTION 71 - CANCELLED | — |
| 044 | Medical services; diagnosis of diseases, namely, medical diagnosis of Familiar Hypercholesterolemia, DLAL (Deficiency in Lysosomal Acid Lipase) and Cardiovascular Risks; medical diagnostic services, testing and analysis, namely, medical diagnostic testing, monitoring and reporting services; genetic testing for diagnostics or treatments for medical purposes; medical information services provided on the Internet, namely, reporting of consumer authorized clinical testing results directly to the patient; Medical consultation and information services in the field of medical products, namely, providing information relating to diagnostic, prophylactic and treatment of Familiar Hypercholesterolemia, DLAL (Deficiency in Lysosomal Acid Lipase) and Cardiovascular Risks; medical, medicinal and pharmaceutical consultation services; medical advisory services; medical information services, namely, providing medical information; medical analyses for the diagnosis and treatment of people, namely, providing medical profiles and medical record analysis and assessments via a website that are designed to provide custom tailored outputs about recommended resources and treatments associated with a defined set of symptoms and concerns, providing on-line medical record analysis services designed to provide patients with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms; Medical testing for diagnostic or treatment purposes, namely, medical testing relating to the diagnosis and treatment of people; Medical testing for diagnostic or treatment purposes, namely, medical laboratory services for the analysis of blood and saliva samples; Medical testing for diagnostic or treatment purposes, namely, medical laboratory services for the analysis of samples obtained from patients; Medical testing for diagnostic or treatment purposes, namely, medical laboratory services for the analysis of blood and saliva samples obtained from patients | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by GENINCODE U.K., LTD.
- Other trademarks owned by FERRER INCODE, S.L.
- Other trademarks owned by FERRER INCODE, S.L.
- Other trademarks owned by FERRER INCODE, S.L.
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named LIPID INCODE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 9, 2024 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Oct 24, 2024 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Oct 24, 2024 | INPC | INVALIDATION PROCESSED | — |
| Oct 10, 2024 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Feb 9, 2024 | C71T | CANCELLED SECTION 71 | — |
| Dec 24, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 25, 2022 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jul 9, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Dec 18, 2020 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Nov 20, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 20, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 24, 2017 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 3, 2017 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 3, 2017 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 25, 2017 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 25, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 9, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 9, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 5, 2017 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Apr 19, 2017 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 19, 2017 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Apr 19, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 31, 2017 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Mar 27, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 27, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 27, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 27, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 27, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 18, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 18, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 16, 2017 | ALIE | ASSIGNED TO LIE | — |
| Feb 6, 2017 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| Feb 3, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 3, 2017 | PETG | PETITION TO REVIVE-GRANTED | — |
| Feb 3, 2017 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Jan 26, 2017 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 25, 2017 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Oct 3, 2016 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 3, 2016 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 16, 2016 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 28, 2016 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 28, 2016 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 28, 2016 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 27, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 20, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| May 10, 2016 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 6, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 5, 2016 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |